Sparsentan
| CAS No. | 254740-64-2 | Cat. No. | BCP23969 |
| Name | Sparsentan | ||
| Synonyms | RE-021; RE021; RE 021; PS-433540; PS 433540; DARA-a; | ||
| Formula | C32H40N4O5S | M. Wt | 592.75 |
| Description | Sparsentan is a Dual angiotensin II and endothelin A receptor antagonist. Retrophin intends to develop RE-021 for orphan indications of severe kidney diseases including Focal Segmental Glomerulosclerosis (FSGS) as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy. RE-021, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies. | ||
| Pathways | GPCR/G Protein | ||
| Targets | Angiotensin Receptor Endothelin Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.